Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction), neprilysin inhibition reduced the risk of cardiovascular death and total hospitalizations by 13%, improved KCCQ by 1.0 points, and had no overall effect on the EuroQol Visual Analog Scale.3,9”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Self-citationThe perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Self-citationSolomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationPhenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and sur- vival times. Appl Stat 2006; 55: 31-9.
Cited by
Items 601–700 of 1,000
Clinical Phenogroups in Heart Failure with Preserved Ejection Fraction
Sorimachi, H., Omote, K., & Borlaug, B. A. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.009 · Cited by 24
Gavina, C., Seabra, D., Valente, F., Bernardo, F., Dinis‐Oliveira, R. J., Santos-Araújo, C., & Taveira‐Gomes, T. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9050149 · Cited by 27
Shen, L., Dewan, P., Ferreira, J. P., Cunningham, J. W., Jhund, P. S., Anand, I. S., Chandra, A., Chiang, L., Claggett, B. L., Desai, A. S., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.070553 · Cited by 24
Self-citationThe Role of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Tzoumas, A., Tapp, D. N., Crousillat, D. R., Honigberg, M. C., Lozano, P. F. R., Aggarwal, N. R., Ebong, I., Briller, J. E., de Oliveira, G. M., Harrington, C. M., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102345 · Cited by 23
Neprilysin as a Biomarker: Challenges and Opportunities
Pavo, N., Prausmüller, S., Bartko, P. E., Goliasch, G., & Hülsmann, M. (2020) · Cardiac failure review · doi:10.15420/cfr.2019.21 · Cited by 24
Volpe, M., Bauersachs, J. K., Bayés‐Genís, A., Butler, J., Solal, A. C., Gallo, G., Deichl, A. S., Khan, M. S., Battistoni, A., Pieske, B. M., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.11.071 · Cited by 23
Self-citationRai, A. K., Lee, B., Gomez, R., Rajendran, D., Khan, M., & Garikipati, V. N. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.612722 · Cited by 24
The Pathophysiology of Afterload Mismatch and Ventricular Hypertrophy
Carabello, B. A. (2021) · Structural Heart · doi:10.1080/24748706.2021.1944708 · Cited by 25
Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus
Jang, S. Y., Jang, J., Yang, D. H., Cho, H., Lim, S. K., Jeon, E., Lee, S. E., Kim, J., Kang, S., Baek, S. H., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01370-y · Cited by 23
Wagdy, K., & Nagy, S. (2021) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2021.17 · Cited by 26
Miñana, G., de la Espriella, R., Palau, P., Llàcer, P., Núñez, E., Santas, E., Valero, E., Lorenzo, M., Núñez, G., Bodí, V., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05328-2 · Cited by 26
Forsyth, F., Blakeman, T., Burt, J., Chew-Graham, C. A., Hossain, M. Z., Mant, J., Sharpley, J., Sowden, E., & Deaton, C. (2022) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvac081 · Cited by 25
Chang, H., Lin, C., Chao, C., Lin, Y., Wang, Y.-C., Liao, C., Huang, J., Lee, Y., Huang, C., Chien, L., et al. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.06.007 · Cited by 24
Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors
Eworuke, E., Welch, E. C., Haug, N. R., Horgan, C. E., Lee, H. S., Zhao, Y., & HUANG, T.-Y. J. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.033 · Cited by 24
The controversial role of beta-blockers in heart failure with preserved ejection fraction
Wernhart, S., Παπαθανασίου, Μ., Rassaf, T., & Luedike, P. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108356 · Cited by 23
Jung, M., & Shin, M. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.271 · Cited by 26
“However, the PARAGON-HF trial reported no significant CV benefit of sacubitril-valsartan over valsartan in HFpEF subjects [58,59].”
Gallo, G., Rubattu, S. D., Autore, C., & Volpe, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065131 · Cited by 25
“06), statistical significance was not reached [90].”
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
Youn, J., Kim, D., Cho, J. Y., Cho, D., Park, S. M., Jung, M., Hyun, J., Cho, H., Park, S., Choi, J., et al. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0047 · Cited by 23
Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
Ding, Y., Wan, L., Zhang, Z., Yang, Q., Ding, J., Qu, Z., & Yu, F. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2222841 · Cited by 23
“The PARAGON-HF clinical trial (efficacy and safety of LCZ696 compared with valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction) also showed a decreasing trend of incidence of death from cardiovascular causes and total hospitalizations for heart failure, although failed to r…”
MethodThe current best drug treatment for hypertensive heart failure with preserved ejection fraction
Rist, A., Sevre, K., Wachtell, K., Devereux, R. B., Aurigemma, G. P., Smiseth, O. A., Kjeldsen, S. E., Julius, S., Pitt, B., Burnier, M., et al. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.008 · Cited by 28
Self-citationFoà, A., Vaduganathan, M., Claggett, B. L., Pabón, M. A., Lu, H. Y., Pfeffer, M. A., Packer, M., Vardeny, O., Rouleau, J. L., Lefkowitz, M. P., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.035 · Cited by 25
Self-citationJiménez‐Marrero, S., Moliner, P., Rodríguez-Costoya, I., Enjuanes, C., Alcoberro, L., Yun, S., González‐Costello, J., Garay, A., Tajes, M., Calero, E., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.07.008 · Cited by 23
Reddy, Y. N. V., Obokata, M., Jones, A. D., Lewis, G. D., Shah, S. J., Abou-Ezzedine, O. F., Fudim, M., Alhanti, B., Stevenson, L. W., Redfield, M. M., et al. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.08.008 · Cited by 24
Self-citationHypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction
Hicklin, H., Gilbert, O. N., Ye, F., Brooks, J., & Upadhya, B. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01093-7 · Cited by 23
Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
Zeng, Q., Zhou, Q., Liu, W., Wang, Y., Xu, X., & Xu, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.636152 · Cited by 26
“More frustratingly, the angiotensin receptor-neprilysin inhibitor sacubitril-valsartan also did not significantly reduce the risk of hospitalization and all-cause death among patients with HFpEF (16).”
BackgroundObesity, inflammation, and heart failure: links and misconceptions
Triposkiadis, F. K., Xanthopoulos, A. V., Starling, R. C., & Iliodromitis, E. K. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10103-y · Cited by 25
New antidiabetic therapy and HFpEF: light at the end of tunnel?
Tadić, M., Sala, C., Saeed, S., Grassi, G. M., Mancia, G., Rottbauer, W., & Cuspidi, C. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10106-9 · Cited by 25
Fritsch, A., Schloemer, P., Mendolia, F., Mütze, T., Jahn‐Eimermacher, A., & on behalf of the Recurrent Event Qualification Opinion Consortium (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2021.1945488 · Cited by 24
“With PARAGON-HF, the first large drug trial in HF including recurrent HHF in the primary endpoint was recently reported (Solomon et al. 2019).”
MethodShah, S. J. (2019) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2019.08.002 · Cited by 26
Self-citationBerger, J. H., Shi, Y., Matsuura, T. R., Batmanov, K., Chen, X., Tam, K., Marshall, M., Kue, R., Patel, J. D., Taing, R., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84515-9 · Cited by 25
Exercise Training in Heart Failure: Current Evidence and Future Directions
Eleyan, L., Gonnah, A. R., Farhad, I., Labib, A., Varia, A., Eleyan, A., Almehandi, A., Al-Naseem, A., & Roberts, D. H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020359 · Cited by 26
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad400 · Cited by 22
Self-citationDrug innovation via integration of traditional Chinese and Western medicine
Li, Z., Yang, L., Kong, L., Sun, H. J., Sun, Y., Chen, X., Yin, F., Yan, G., & Wang, X. (2025) · Science of Traditional Chinese Medicine · doi:10.1097/st9.0000000000000070 · Cited by 23
Landsteiner, I., Verwerft, J., Belov, D., Verbrugge, F. H., & Lewis, G. D. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag175 · Cited by 29
Abumayyaleh, M., El‐Battrawy, I., Behnes, M., Borggrefe, M. M., & Akın, İ. (2020) · Future Cardiology · doi:10.2217/fca-2020-0002 · Cited by 24
Heart Failure and Drug Therapies: A Metabolic Review
Yu, F., McLean, B., Badiwala, M., & Billia, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062960 · Cited by 24
Jia, R., Zhang, X., Xu, Y., Zheng, Z., Jiang, L., Zhang, X., Sun, C., Wu, X., Li, S., Raj, A., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175053 · Cited by 23
Improving implementation of evidence‐based therapies for heart failure
DeVore, A. D., Bosworth, H. B., & Granger, B. B. (2022) · Clinical Cardiology · doi:10.1002/clc.23845 · Cited by 22
Targets and management of hypertension in heart failure: focusing on the stages of heart failure
Miao, H., Zou, C., Yang, S., Chia, Y. C., Minh, H. V., Sogunuru, G. P., Tay, J. C., Wang, T., Kario, K., & Zhang, Y. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14553 · Cited by 24
Biomarkers in HFpEF for Diagnosis, Prognosis, and Biological Phenotyping
Eltelbany, M., Shah, P. M., & deFilippi, C. R. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00578-7 · Cited by 22
Ageev, F. T., & Ovchinnikov, A. G. (2023) · Kardiologiia · doi:10.18087/cardio.2023.3.n2376 · Cited by 26
Stolfo, D., Lund, L. H., Sinagra, G., Lindberg, F., Dahlström, U., Rosano, G. M. C., & Savarese, G. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad036 · Cited by 22
Matsumoto, S., Kondo, T., Yang, M., Campbell, R. T., Docherty, K. F., de Boer, R. A., Desai, A. S., Lam, C. S. P., Packer, M., Pitt, B., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3044 · Cited by 23
Self-citationTrends in Mortality After Incident Hospitalization for Heart Failure Among Medicare Beneficiaries
Vohra, A. S., Moghtaderi, A., Luo, Q., Magid, D. J., Black, B. S., Masoudi, F. A., & Kini, V. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.28964 · Cited by 23
Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy
Sava, R., Pepine, C. J., & March, K. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010241 · Cited by 23
“Although sacubitril-valsartan did not reduce the rate of hospitalization for HFpEF and total cardiovascular deaths, signals of efficacy arose from subgroup analysis, suggesting that PKG modulation may be effective in women and patients with a lower ejection fraction (EF) [14].”
BackgroundA Registry-Based Algorithm to Predict Ejection Fraction in Patients with Heart Failure
Uijl, A., Lund, L. H., Vaartjes, I. C. H., Brugts, J. J., Linssen, G. C. M., Asselbergs, F. W., Hoes, A. W., Dahlström, U., Koudstaal, S., & Savarese, G. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12779 · Cited by 22
Toth, P. P., & Gauthier, D. F. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1842620 · Cited by 23
Shah, S. J., Cowie, M., Wachter, R., Szecsödy, P., Shi, V. C., Ibram, G., Hu, M., Zhao, Z., Gong, J., & Pieske, B. M. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2277 · Cited by 23
Self-citationHernandez, M., Sullivan, R. D., McCune, M. E., Reed, G. L., & Gladysheva, I. P. (2022) · Diagnostics · doi:10.3390/diagnostics12040989 · Cited by 23
Maryniak, A., Maisuradze, N., Ahmed, R., Biskupski, P., Joseph, J., & Budzikowski, A. S. (2022) · Cardiology Journal · doi:10.5603/cj.a2022.0051 · Cited by 23
“A subsequent pooled meta-analysis that www.cardiologyjournal.org 675 combined the PARAGON-HF and PARADIGM-HF trials, identified a graded benefit of angiotensinneprilysin inhibition depending on measured EF.”
BackgroundInfluentialHeart Failure and Diabetes Mellitus: Dangerous Liaisons
Lee, H. (2022) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0022 · Cited by 24
Ejection fraction in heart failure revisited- where does the evidence start?
Böhm, M., Bewarder, Y., & Kindermann, I. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa281 · Cited by 22
Gupta, M., Bell, A., Padarath, M., Ngui, D., & Ezekowitz, J. A. (2020) · CJC Open · doi:10.1016/j.cjco.2020.11.008 · Cited by 21
“Such gaps, if shown, might then support new initiatives to optimize the care of patients with HFpEF.”
ResultInfluentialScheffer, M., Driessen‐Waaijer, A., Hamdani, N., Landzaat, J. W. D., Jonkman, N. H., Paulus, W. J., & van Heerebeek, L. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13055 · Cited by 21
Sanna, G. D., Canonico, M. E., Santoro, C., Esposito, R., Masia, S. L., Galderisi, M., Parodi, G., & Nihoyannopoulos, P. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00530-1 · Cited by 23
Funes, D. R., Blanco, D. G., Fonnegra, C. B., Liang, H., Menzo, E. L., Szomstein, S., & Rosenthal, R. J. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.09.009 · Cited by 21
Shao, H., Fang, C., Huang, Y., Ye, Y., & Tong, R. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153879 · Cited by 21
Yang, D., Zhang, Y., Yan, J. R., Liu, M. R., & An, F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.942125 · Cited by 22
A Systematic Review of Sex-Specific Reporting in Heart Failure Clinical Trials
Au, M., Whitelaw, S., Khan, M. S., Mamas, M. A., Mbuagbaw, L. C. E., Mulvagh, S. L., Voors, A. A., & Spall, H. G. C. V. (2022) · JACC Advances · doi:10.1016/j.jacadv.2022.100079 · Cited by 24
Wernhart, S., Παπαθανασίου, Μ., Mahabadi, A. A., Rassaf, T., & Luedike, P. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.10.009 · Cited by 21
Heart Failure in Menopause: Treatment and New Approaches
da Silva, J. S., Montagnoli, T. L., de Sá, M. P. L., & Zapata‐Sudo, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315140 · Cited by 23
Cho, J. Y., Cho, D., Youn, J., Kim, D., Park, S. M., Jung, M., Hyun, J., Choi, J., Cho, H., Park, S., et al. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0046 · Cited by 22
Role of splanchnic circulation in the pathogenesis of heart failure: State-of-the-art review
Yaku, H., Fudim, M., & Shah, S. J. (2024) · Journal of Cardiology · doi:10.1016/j.jjcc.2024.02.004 · Cited by 22
Self-citationFukuma, N., Tokiwa, H., Numata, G., Ueda, K., Liu, P., Tajima, M., Otsu, Y., Kariya, T., Hiroi, Y., Liao, J. K., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae202 · Cited by 21
“7,8 Considering the mechanism of action for ARNi as cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) activation, the cGMP-PKG pathway might be specifically involved in the pathophysiology of heart failure in women following menopause.”
Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
Cersosimo, A., Drera, A., Adamo, M., Metra, M., & Vizzardi, E. (2024) · Kidney and Dialysis · doi:10.3390/kidneydial4040016 · Cited by 24
Tafelmeier, M., Baessler, A., Wagner, S., Unsöld, B. W., Preveden, A., Barlocco, F., Tomberli, A., Popović, D., Brennan, P., MacGowan, G. A., et al. (2020) · Clinical Cardiology · doi:10.1002/clc.23346 · Cited by 23
“The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/ valsartan is a novel treatment shown to reduce hospitalizations and mortality in heart failure with reduced ejection fraction,(10) while there was no significant benefit of sacubitril/valsartan on the rate of total hospitalizations for heart failure and…”
BackgroundTargets of cGMP/cGKI in Cardiac Myocytes
Adler, J., Kuret, A., Längst, N., & Łukowski, R. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000817 · Cited by 22
Cui, X., Thunström, E. Ö., Dahlström, U., Zhou, J., Ge, J., & Fu, M. L. X. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12899 · Cited by 21
Self-citationInteratrial shunt devices for the treatment of heart failure
Emani, S., Burkhoff, D., & Lilly, S. M. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.09.004 · Cited by 23
Smith, K. T., Lang, C. C., Wingham, J., Frost, J., Greaves, C. J., Abraham, C., Warren, F. C., Coyle, J., Jolly, K. B., Miles, J., et al. (2021) · Pilot and Feasibility Studies · doi:10.1186/s40814-020-00747-2 · Cited by 21
Rohde, L. E. P., Claggett, B. L., Wolsk, E., Packer, M., Zile, M. R., Swedberg, K. B., Rouleau, J. L., Pfeffer, M. A., Desai, A. S., Lund, L. H., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.008052 · Cited by 23
Self-citationObesity and Heart Failure with Preserved Ejection Fraction
Koutroumpakis, E., Kaur, R., Taegtmeyer, H., & Deswal, A. M. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.003 · Cited by 25
Herzinsuffizienzleitlinien 2021 der ESC
Bauersachs, J. K., & Soltani, S. (2021) · Herz · doi:10.1007/s00059-021-05084-5 · Cited by 23
Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
Cappetta, D., Angelis, A. D., Bellocchio, G., Telesca, M., Cianflone, E., Torella, D., Rossi, F., Urbanek, K., & Berrino, L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.810791 · Cited by 23
“may benefit in terms of hospitalization and CV death (26).”
BackgroundMandoli, G. E., Pastore, M. C., Giannoni, A., Benfari, G., Dini, F. L., Rosa, G., Pugliese, N. R., Taddei, C., Correale, M., Brunetti, N. D., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14155 · Cited by 22
Carson, P. E., Teerlink, J. R., Komajda, M., Anand, I. S., Anker, S. D., Butler, J., Doehner, W., Ferreira, J. P., Filippatos, G. S., Haass, M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.11.017 · Cited by 23
Self-citationImpact of Pneumonia in Heart Failure Patients
MANCINI, D. M., & Gibson, G. T. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.010 · Cited by 21
Rajzer, P., & Biegus, J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-024-10471-1 · Cited by 21
Lu, H. Y., Claggett, B. L., Minamisawa, M., Ostrominski, J. W., Foà, A., Pabón, M. A., Kalaycı, A., Vaduganathan, M., Čikeš, M., Shah, A. M., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038872 · Cited by 23
Self-citationHeart failure in the elderly: epidemiology, mechanisms, and management
de Boer, R. A., Abdellatif, M., Bauersachs, J. K., & Roger, V. L. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag110 · Cited by 24
“…76 years), 97 the Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction (PARAGON-HF, mean age 73 years), 98 and the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure trial (DELIVER, mean age 72…”
Hypertension and Heart Failure with Preserved Ejection Fraction
Lee, C. J., & Park, S. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.002 · Cited by 21
Vaishnav, J., Yanek, L. R., Hahn, V. S., Yang, E., Trivedi, R. K., Kass, D. A., & Sharma, K. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.12.007 · Cited by 20
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
Heath, R., Johnsen, H. S., Strain, W. D., & Evans, M. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01204-4 · Cited by 23
“There were reduced hospitalisation trends for candesartan [15], spironolactone [16] and sacubitril/valsartan [17] but no significant”
BackgroundA Bibliometric Analysis of Heart Failure with Preserved Ejection Fraction From 2000 to 2021
Zhang, X., Zhou, Y., Wei, N., Shou, X., Fan, S., You, Y., Li, Y., & Hu, Y. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101243 · Cited by 21
Straw, S., Cole, C. A., McGinlay, M., Drozd, M., Slater, T. A., Lowry, J. E., Paton, M. F., Levelt, E., Cubbon, R. M., Kearney, M. T., et al. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02053-8 · Cited by 20
“On the other hand, consistent with the lack of clinical trial evidence for HFpEF [17, 18] treatments offered to this group attending our service were limited to lifestyle and risk factor modification as well as loop diuretics for alleviation of symptoms of congestion.”
Mechanisms of current therapeutic strategies for heart failure: more questions than answers?
Khan, M. S., Shahid, I., Greene, S. J., Mentz, R. J., DeVore, A. D., & Butler, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac187 · Cited by 22
Characteristics and Outcomes of Patients with a History of Cancer Recruited to Heart Failure Trials
Dobbin, S. J. H., Shen, L., Petrie, M. C., Packer, M., Solomon, S. D., McMurray, J. J. V., Lang, N. N., & Jhund, P. S. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2818 · Cited by 20
Self-citationObesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling
Stencel, J. D., Alai, H. R., Dhore-Patil, A., Urina‐Jassir, D., & Jemtel, T. H. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093341 · Cited by 27
Dalal, J. J., Chandra, P., Ray, S., Hazra, P. K., Hiremath, J., Kumar, V., Shah, M., Abdullakutty, J., Ghosh, D., Vasudevan, K., et al. (2023) · Cardiology and Therapy · doi:10.1007/s40119-023-00323-8 · Cited by 21
“In patients with HFpEF, an analysis of the CKD subgroup in the PARAGON-HF study revealed a 50% reduction in the risk of the renal composite endpoint when comparing ARNI to ARB [51].”
ResultPPP1R12C Promotes Atrial Hypocontractility in Atrial Fibrillation
Perike, S., González-González, F. J., Abu-Taha, I., Damen, F. W., Hanft, L. M., Lizama, K. S., Aboonabi, A., Capote, A. E., Aguilar-Sánchez, Y., Levin, B. S., et al. (2023) · Circulation Research · doi:10.1161/circresaha.123.322516 · Cited by 20
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management
Bhatt, A. S., Vaduganathan, M., Claggett, B. L., Fonarow, G. C., Packer, M., Pfeffer, M. A., Shah, S. J., Shen, X., Cristino, J. R., McMurray, J. J. V., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.3216 · Cited by 20
Self-citationWhy Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?
Kondo, T., Henderson, A. D., Docherty, K. F., Jhund, P. S., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.033 · Cited by 20
Self-citationChoi, H., & Shin, M. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.105 · Cited by 20
“In the prespecified subgroup analysis, female patients and patients with LVEF ≤ 57% showed greater reduction in the primary endpoint after ARNI treatment, suggesting that subsets of HFpEF patients may benefit from sacubitril/valsartan [38].”
MethodPalazzuoli, A., Ruocco, G. M., & Gronda, E. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09972-6 · Cited by 23
Gallo, G., Tocci, G., Fogacci, F., Battistoni, A., Rubattu, S., & Volpe, M. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.05.084 · Cited by 16
Sex-related differences in chronic heart failure: a community-based study
Russo, G. L., Rea, F., Barbati, G., Cherubini, A., Stellato, K., Scagnetto, A., Iorio, A., Corrao, G., & Lenarda, A. D. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001049 · Cited by 20
Nagai, T., Nakao, M., & Anzai, T. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-1299 · Cited by 20
Kim, Y. S., Brar, S. K., Dalbo, N., Dey, A. K., Shah, S. P., Ganatra, S., & Dani, S. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07210-1 · Cited by 22
Self-citationMonda, V. M., Gentile, S., Porcellati, F., Satta, E., Fucili, A., Monesi, M., & Strollo, F. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02310-2 · Cited by 22
The Potential Role of Renal Denervation in the Management of Heart Failure
Kassab, K., Soni, R., Kassier, A., & Fischell, T. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144147 · Cited by 19
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., Comin-Colet, J., Cleland, J., Düngen, H.-D., Goncalvesova, E., Katova, T., Kerr Saraiva, J. F., Lelonek, M., Merkely, B., Senni, M., Shah, S. J., Zhou, J., Rizkala, A. R., Gong, J., Shi, V. C., & Lefkowitz, M. P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Anand, Inder S.
- Ge, Junbo
- Lam, Carolyn S.P.
- Maggioni, Aldo P.
- Packer, Milton
- Pfeffer, Marc A.
- Pieske, Burkert
- Redfield, Margaret M.
- Rouleau, Jean L.
- Zannad, Faiez
- Zile, Michael R.
- Desai, Akshay S.
- Claggett, Brian
- Jhund, Pardeep S.
- Boytsov, Sergey A.
- Cleland, John
- Düngen, Hans-Dirk
- Lelonek, Małgorzata
- Senni, Michele
- Shah, Sanjiv J.
- Zhou, Jingmin
- Rizkala, Adel R.
- Gong, Jianjian
- Shi, Victor C.
- Lefkowitz, Martin P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1609-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971294569
- Cited by
- 2,430
- References
- 25
- Citations by year
- 2026: 258 · 2025: 296 · 2024: 338 · 2023: 361 · 2022: 414 · 2021: 385 · 2020: 318 · 2019: 55
- FWCI
- 211.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- sacubitril/valsartan, valsartan, angiotensin receptor-neprilysin inhibition, heart failure with preserved ejection fraction, heart failure hospitalization, cardiovascular mortality, NYHA functional class, renal function, Kansas City Cardiomyopathy Questionnaire, natriuretic peptides, structural heart disease, drug safety, adverse events, anemia of chronic kidney disease, hyperkalemia
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angioedema, Biphenyl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Quality of Life, Sex Factors, Stroke Volume, Tetrazoles, Neprilysin, Single-Blind Method, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.